Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

• Váldodahkkit: Adnan Asif Parvez Ghias (Dahkki), Shahzeem Bhayani (Dahkki), David J. Gemmel (Dahkki), Sudershan K. Garg (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Greater Baltimore Medical Center, 2018-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to 6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has shown a survival benefit in GISTs, and the presence of KIT mutation status is predictive of response. The current case...